AETA peptide contributes to Alzheimer’s disease signature of synapse dysfunction - Summary - MDSpire

AETA peptide contributes to Alzheimer’s disease signature of synapse dysfunction

  • By

  • Jade Dunot

  • Carine Gandin

  • Marin Truchi

  • Giulia Pirro

  • Sébastien Moreno

  • Agathe Launay

  • Benjamin Azoulay

  • Hugo Landra

  • Sandy Ma Yishan

  • Luc Buée

  • Kevin Lebrigand

  • Paula A. Pousinha

  • David Blum

  • Bernard Mari

  • Ingrid Bethus

  • Michael Willem

  • Hélène Marie

  • June 3, 2026

  • 0 min

Share

Objective:

To investigate the role of AETA in synaptic dysfunction related to Alzheimer’s disease (AD) and its potential as a therapeutic target, highlighting its significance in the pathology of AD.

Approach:
    Key Findings:
    • AETA levels increase in human AD patient brains, suggesting a potential biomarker.
    • Mimicking elevated AETA in rodent models leads to synaptic dysfunction and memory decay, indicating a causal relationship.
    • AETA inhibits NMDA receptor activity and promotes non-canonical signaling, reducing synaptic strength, which may inform therapeutic strategies.
    Interpretation:

    AETA is implicated as a critical mediator of synaptic pathology in AD, contributing to cognitive decline through its effects on NMDA receptor signaling, contrasting with other known factors like Aβ and Tau.

    Limitations:
    • The precise molecular mechanisms by which AETA contributes to synaptic dysfunction are not fully elucidated, warranting further investigation.
    • The study primarily focuses on rodent models, which may not fully replicate human AD pathology; future studies should aim to bridge this gap.
    Conclusion:

    AETA may serve as a potential therapeutic target for addressing synaptic dysfunction in Alzheimer’s disease, emphasizing the need for targeted research in this area.

Original Source(s)

AETA peptide contributes to Alzheimer’s disease signature of synapse dysfunction

  • by Jade Dunot, Carine Gandin, Marin Truchi, Giulia Pirro, Sébastien Moreno, Agathe Launay, Benjamin Azoulay, Hugo Landra, Sandy Ma Yishan, Luc Buée, Kevin Lebrigand, Paula A. Pousinha, David Blum, Bernard Mari, Ingrid Bethus, Michael Willem, Hélène Marie

  • June 3, 2026

Related Content

Impact of hypertension history and blood pressure parameters on cognitive impairment in patients with atrial fibrillation: a systematic review and meta-analysis

Agitation, Alzheimer’s disease, and autophagy: mechanistic insights into aging pathways, gut microbiome, and artificial intelligence

Home Health Value-Based Purchasing and Postacute Home Health Visits Among Older Adults With Dementia